Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.
1 report, 1 independent
Updated Sep 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Genmab
Danish healthcare company
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
-
TD Cowen
American investment bank
Related events
- Truist Financial boosted price target and gave buy rating, and TD Cowen lifted target price and gave buy rating for Encompass Health.
- Truist Financial and TD Cowen provided rating and price targets for SiBone shares.
- Truist Financial raised its target price on Teva Pharmaceutical Industries Ltd. stock.
- Rating firms Raymond James Financial and TD Cowen provided reaffirmed buy ratings and price targets for a company listed on Nasdaq.
- FirstCash received price target and rating upgrades from TD Cowen, filed 13F with the SEC, and traded on Nasdaq.